Alpine Immune Sciences named a best idea for 2024 at TD Cowen

TD Cowen named Alpine Immune Sciences a best idea for 2024 while keeping an Outperform rating on the shares. The analyst says povetacicept’s 24-week UPCR reduction at 80 mg is higher than any in the class, and the possibility for improvement at 240 mg in the first half of 2024 is “underappreciated as it could solidify its leading profile.”